Arnulf Stenzl, MD, presented “Population of Men with Advanced Prostate Cancer: Sequencing of Treatment” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Stenzl, Arnulf. “Population of Men with Advanced Prostate Cancer: Sequencing of Treatment.” October 8, 2024. Accessed Feb 2025. https://grandroundsinurology.com/population-of-men-with-advanced-prostate-cancer-sequencing-of-treatment/
Population of Men with Advanced Prostate Cancer: Sequencing of Treatment – Summary
In an 11-minute presentation, Arnulf Stenzl, MD, delves into the evolving landscape of sequencing treatments for advanced prostate cancer, emphasizing integrating technology and data to optimize patient care. He begins with the challenges posed by the increasing complexity of treatment options, advocating for personalized, patient-centered approaches that extend beyond rigid guidelines.
Dr. Stenzl underscores the role of real-world data in complementing clinical trial findings, citing initiatives like the Euro Evidence Hub and Optima Project. AI and large language models, such as ChatGPT, are proposed as tools to bridge gaps in patient understanding and clinician efficiency. Early studies suggest that AI-generated responses often outperform traditional communication methods in clarity and relevance.
A key focus is the overwhelming volume of prostate cancer research. AI-assisted platforms promise to streamline this process, enabling personalized treatment plans by integrating clinical records, imaging, and trial data.
Stenzl highlights AI as an aid to clinicians and patients, improving their ability to manage complex cases efficiently while reducing burnout.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Arnulf Stenzl, MD is Chairman and Professor in the Department of Urology at the Eberhard Karls University of Tuebingen Medical School. Dr. Stenzl earned his MD from the Karl-Franzens University in Graz, Austria.
Dr. Stenzl is author or co-author on more than 800 publications and scientific papers in peer reviewed journals, and he is a member of numerous public and privately initiated steering committees and advisory boards focusing on urologic topics. Dr. Stenzl holds two international patents. Dr. Stenzl has been the Chairman of the Scientific Congress Office of the European Association of Urology (EAU), Adjunct Secretary Science of the EAU and Secretary-elect since 2022. Dr. Stenzl is a Board member of the European Cancer Organization and was president of the German Association of Urology in 2020/2021. He is also on the editorial boards of several journals.
Dr. Stenzl’s major research interests are bladder and prostate cancer and reconstructive urology. He has been awarded the Jackson Hole Award of Excellence in the United States. Additionally Dr. Stenzl is an investigator in numerous clinical trials and has organized numerous national and international symposiums on uro-oncology, particularly prostate and bladder cancer, as well other urologic subjects.
In May 2017 he was granted an honorary degree because of his worldwide recognition and contribution to the development in the field of urology.
